发明名称 |
CD20 antibodies and uses thereof |
摘要 |
CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). The present invention includes anti-CD20 antibodies and antigen-binding fragments thereof comprising a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs: 17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively. |
申请公布号 |
US9173961(B2) |
申请公布日期 |
2015.11.03 |
申请号 |
US201113024556 |
申请日期 |
2011.02.10 |
申请人 |
ImmunoGen, Inc. |
发明人 |
Deckert Jutta;Rui Lingyun;Park Peter U. |
分类号 |
A61K39/395;C07K16/28;C07K16/30;A61K47/48;G01N33/574;A61K51/10;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
代理人 |
Sterne, Kessler, Goldstein & Fox P.L.L.C. |
主权项 |
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to CD20, wherein said antibody or fragment comprises a light chain variable region and a heavy chain variable region, wherein the CDR-L1, CDR-L2, and CDR-L3 of said light chain variable region comprise the amino acid sequences of SEQ ID NOs:17-19, respectively, and wherein the CDR-H1, CDR-H2, and CDR-H3 of said heavy chain variable region comprise the amino acid sequences of SEQ ID NOs: 20-22, respectively. |
地址 |
Waltham MA US |